Biotech stocks have been on a wild (and underwhelming) ride this year, with the iShares Biotechnology ETF (IBB) dropping 3.3% year to date as the rest of the market ripped higher on the back of technology names.
Although it's been quite a slog for the broader basket of biotech and pharmaceutical stocks, I view some of them as intriguing value picks to play a potential wave of economic volatility brought forth by rate hikes and sagging economic growth.
